The finding, described as the first to test possible medical uses of so-called ATP-synthase inhibitors, may lead to new and more effective anti-cancer medications, according to a new report.

Citreoviridin, which is in the same class as aurovertin, targets the β subunit of the F1-ATP synthase, inhibits the growth and proliferation of BC cells as well as lung adenocarcinoma cells.

The commonly observed symmetry is broken by the accommodation of a single subunit at the dimer interface that anchors an inhibitor. In addition, the ATP synthase has an unusual U-shape arrangement ...

More information: Gautier M Courbon et al, Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines, The EMBO Journal (2023). DOI: 10.15252/embj ...

In addition to informing the development of TBAJ-876 and SQ31f, these findings also offer fresh insights into the molecular mechanisms that make some ATP synthase inhibitors more effective at ...

PHILADELPHIA—A novel selective aldosterone synthase (AS) inhibitor, BI690517, may improve the therapeutic ability to slow chronic kidney disease (CKD) progression, an investigator reported at ...